Which of the following supports a strategy by a biotech firm to license (meaning permit) a drug to a pharmaceutical company for manufacturing and distribution?
A.
The biotech firm has a patent on the drug.
B.
The biotech firm has excess drug making capacity.
C.
The pharmaceutical company can easily appropriate the innovative drug.
D.
The biotech firm has an extensive distribution network.